A Multicenter Phase 1A/1B Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 Dec 2016
At a glance
- Drugs Altiratinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Deciphera Pharmaceuticals
- 13 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Jul 2016 Planned number of patients changed from 48 to 105.
- 14 Jul 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2017.